Antengene Will Present Cos-TCE Results at SITC 2026
The company will unveil its preclinical T cell engager platform data in Phoenix this November.
Updated on Oct. 3, 2026 in Biotech
Antengene is scheduled to present preclinical data for its Cos-TCE platform at the 2026 SITC Annual Meeting on November 6, 2026. The platform utilizes a unique CD2-based costimulatory approach to address solid tumor treatments.
Why it matters
This platform design intends to improve the therapeutic window of T cell engagers by enhancing efficacy while reducing the risk of cytokine release syndrome. The presentation will offer technical insights into how the company manages target-binding kinetics to improve patient safety.
The Cos-TCE platform features 2+1 bivalent binding for low-expressing targets and utilizes proprietary CD3 sequences with fast on/off kinetics. It integrates a CD3γε/δε-targeting antibody with steric-hindrance-based CD3 masking.
The players
Antengene
Antengene is a biopharmaceutical company based in Shanghai and Hong Kong that focuses on innovative oncology therapies.
Dr. Bing Hou
Dr. Bing Hou is the researcher designated to lead the oral presentation of the Cos-TCE platform data.
The details
The platform was engineered to solve common challenges in oncology drug development, such as tumor specificity and immune system overreaction. By implementing a 2+1 binding architecture, the system is designed to trigger T cell activation more precisely than conventional methods.
Timeline
The 2026 SITC Annual Meeting takes place in Phoenix from November 4 to 8, 2026.
The official Rapid Oral Abstract Presentation will occur on November 6, 2026.
The Tech Race
This development reflects the broader trend of engineering next-generation bispecific and trispecific antibodies to replace legacy immunotherapy approaches. It positions Antengene within the competitive field of T cell redirection, aiming to overcome the dose-limiting toxicities of earlier platforms.
The potential success of this platform could eventually lead to safer and more effective treatment options for cancer patients by mitigating the severe side effects often associated with current T cell therapies. It marks a shift toward highly engineered, programmable therapeutics that may require less intensive hospital-based management for patients.
The takeaway
The evolution of T cell engagers toward CD2-based costimulation represents a strategic pivot to address the limitations of existing immune-oncology agents. As these platforms move closer to clinical application, investors and oncologists will be watching for durability and safety signals.
What happens next
The formal presentation of the Cos-TCE preclinical data (Abstract number 15749) is scheduled for November 6, 2026, during the SITC Annual Meeting.
Further reading
Learn more about the latest innovations in clinical development and research on our Biotech page.
